CeleCor Therapeutics

We're excited that the Emergency Department at Corewell Health William Beaumont University Hospital and Corewell Health Troy Teams lead by Carol Clark will be enrollling patients in the #CeleBrate Trial.

SEASONS GREETINGS! We would like to take a moment to wish you and your loved ones the very best for the Holiday Season and a Happy New Year! CeleCor Therapeutics

Acute Myocardial Infarction (AMI) continues to be a leading cause of death worldwide, with a rising incidence linked to aging populations and increasing risk factors. As the global AMI burden grows, advancements in treatment options, including innovative therapies and precision medicine, are reshaping patient outcomes. The market for AMI treatment is expected to expand significantly by 2034, driven by evolving technologies and a greater focus on prevention. The key Acute Myocardial Infarction companies in the market include - Idorsia Pharmaceuticals Ltd, Viatris, AstraZeneca, Boehringer Ingelheim, Bayer, Faraday Pharmaceuticals, Inc., #CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, JNJ, CellProthera SAS, BioCardia, Inc., Kancera, Amgen, Arrowhead Pharmaceuticals, New Amsterdam , and others. AcuteMyocardialInfarction #HeartHealth #AMI #CardiovascularDisease #MarketInsights #HeartAttack #Epidemiology #HealthTech #MedicalResearch #MarketForecast #Healthcare #Cardiology #Innovation

Thank you to everyone who joined us at the #CVCTForum in Washington, D.C. 🙏 It was exciting to present at #CVCT2024 along side C. Michael Gibson, M.S., M.D. on pre- hospital treatment of patients with heart attacks. Also thank you to all other speakers and panelists for sharing your knowledge, and to chairpersons Renato Lopes and Mpiko Ntsekhe for leading the session. #cardiovascularresearch #hearthealth #heartattack #heartdisease #treatment CVCT - Cardiovascular Clinical Trialists

✨ Join Celecor at the CVCT - Cardiovascular Clinical Trialists Forum. We're delighted to participate in the upcoming #CVCTForum at the Mayflower Hotel in Washington, DC. 📅 Date: Monday, December 9th, 2024 🕚 Time: 11:00 AM - 1:00 PM 📍 Session: Thrombosis Trials – New Drugs – Challenging Indications 🗣️ Chairpersons: Renato Lopes & Mpiko Ntsekhe Our CEO Robert S. Hillman will share industry viewpoints, and C. Michael Gibson, M.S., M.D. will discuss Prehospital anti-thrombotic trials in STEMI. We'll close the session with the Multi-Stakeholder Think Tank Debate. Don’t miss this opportunity to connect with peers, exchange ideas, and explore the future of cardiovascular care. Let us know if you’ll be there! #CardiovascularResearch #InnovationInMedicine

📣 New Milestone in CeleBrate Phase 3 Trial: U.S. Sites Join the Study! We’re excited to share that U.S. enrollment is now underway in the CeleBrate STEMI Study! Three exceptional sites have joined the trial, marking a key step forward in our mission to advance STEMI treatment in the pre-hospital setting. Introducing Our U.S. Sites: 📍 ALASKA CARDIOVASCULAR RESEARCH FOUNDATION INC/Alaska Fire Department (Anchorage, AK) Led by Dr. Jon McDonagh, MD, FACC (PI), interventional cardiologist, and Dr. Michael Levy (Sub-PI), CMO of Anchorage Areawide EMS. 📍 Washington University in St. Louis (St. Louis, MO) Guided by Dr. Douglas Char (PI), Professor of Emergency Medicine, and Dr. Stacey House (Sub-PI), Vice Chair for Clinical Research. 📍 Baylor College of Medicine/Ben Taub (Houston, TX) Headed by Dr. Richard Kuo (PI), Chair of Emergency Medicine, alongside Co-PIs Dr. Richina Bicette (Emergency Medicine), Dr. Xiaomin Jia (Cardiology), and Dr. Mahboob Alam (Cardiology). 🙏 A heartfelt thank you to the teams at these sites for their perseverance and dedication in reaching this important milestone. Your commitment makes a difference. 📢 Stay tuned for more updates as the CeleBrate Trial progresses. #clinicaltrials #cardiology #medicalresearch #stemi #emergencymedicine #innovation #zalunfiban

Excited for Dr. Barry Coller’s upcoming presentation, “From αIIbβ3 to αVβ3" at the #AHA2024 Education Symposisum on November 16, 2024 from 1:45-2:00PM in Chicago, IL. Under the theme “Blood Fuels the Heart: The Discovery, Development, and Future of Anti-Platelet Therapy in Cardiovascular Diseases,” Dr. Coller will discuss his groundbreaking work, including the development of #ReoPro (abciximab) and #Zalunfiban (RUC-4) for the treatment of patients experiencing heart attacks. Don’t miss this opportunity to hear firsthand about his critical contributions to cardiovascular medicine. #cardiovasculardisease #antiplatelettherapy

We're delighted to have Sem Rikken present "TCT 329: Pharmacokinetics of 14C-Labeled Zalunfiban (RUC-4) Suggests That No Dose Adjustment Is Necessary for Impaired Renal Function". 📅 Date: Wednesday, October 30, 2024 ⏰ Time: 8:45 AM 📍 Session: CKD, AKI, and Contrast Management-2 | TCT2024 This presentation will be on behalf of Robert B. MacArthur, PharmD, MS, BCSCP, Barry Coller, C. Michael Gibson, M.S., M.D., Chris Granger, Gilles Montalescot, Jur ten Berg, and Arnoud van 't Hof. 💡 Exciting new data emerging about #zalufiban and its potential role in treating patients with heart attacks. #TCT2024 #hearthealth #cardiology #pharmacokinetics

CeleCor in action... Racing to completion of #CeleBrate trial with #zalunfiban !!!

The #CeleBrate team wants to congratulate Executive Committee member, Professor Gilles Montalescot for receiving the Grand Prix Scientifique 2024. The Grand Prix was awarded to Professor Gilles Montalescot, Head of the cardiology department at the Pitié-Salpêtrière AP-HP hospital, as a recognition for his research in the cardiovascular field and having initiated and directed numerous large-scale randomized clinical trials To reward researchers and promote the development of clinical research, Fondation de l'AP-HP awarded scientific prizes to AP-HP medical and paramedical staff who have made decisive advances in their professional practice for the future of medicine and have contributed with determination to improving patient care. The award ceremony took place on October 15, 2024.